- Home
- AVX vs MREO Comparison
AVX vs MREO Comparison
Compare AVX & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVX | MREO |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | Canada | United Kingdom |
| Employees | 7 | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.6M | 52.5M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | AVX | MREO |
|---|---|---|
| Price | $0.52 | $0.24 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 604.7K | ★ 1.7M |
| Earning Date | 05-15-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $500,000.00 |
| Revenue This Year | N/A | $5,184.20 |
| Revenue Next Year | N/A | $55.51 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.44 | $0.20 |
| 52 Week High | $2.27 | $2.94 |
Technical Indicators
Market Signals| Indicator | AVX | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 45.10 | 30.74 |
| Support Level | $0.46 | $0.20 |
| Resistance Level | $0.60 | $0.36 |
| Average True Range (ATR) | 0.04 | 0.03 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 53.72 | 21.64 |
Price Performance
Historical ComparisonAbout AVX Avax One Technology Ltd.
AVAX One Technology Ltd is a public company offering investors regulated access to the Avalanche (AVAX) ecosystem. By integrating the reliability of U.S. capital markets with the growth potential of decentralized finance, it seeks to create a bridge between traditional and digital finance. It focuses on building a digital-asset treasury, fostering innovation, and investing in decentralized financial technologies that benefit from the Avalanche network.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).